ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Bio Path Holdings Inc

Bio Path Holdings Inc (BPTH)

2.03
0.02
(1.00%)
Closed May 26 4:00PM
2.11
0.08
(3.94%)
After Hours: 5:45PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
2.11
Bid
0.6501
Ask
3.00
Volume
76,780
2.00 Day's Range 2.10
2.00 52 Week Range 44.80
Market Cap
Previous Close
2.01
Open
2.01
Last Trade
18
@
2.0016
Last Trade Time
Financial Volume
$ 156,599
VWAP
2.0396
Average Volume (3m)
1,537,838
Shares Outstanding
678,795
Dividend Yield
-
PE Ratio
-0.08
Earnings Per Share (EPS)
-23.69
Revenue
-
Net Profit
-16.08M

About Bio Path Holdings Inc

Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The comp... Bio-Path Holdings Inc is a clinical and preclinical stage oncology-focused RNAi nanoparticle drug development company. It is engaged in utilizing a novel technology that achieves systemic delivery for target-specific protein inhibition for any gene product that is over-expressed in disease. The company's lead drug candidate, prexigebersen, is in the efficacy portion of Phase 2 clinical trial for acute myeloid leukemia (AML) in combination with low-dose cytarabine (LDAC) and combination with decitabine. Its other drugs are BP1002 and BP1003. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Dover, Delaware, USA
Founded
1970
Bio Path Holdings Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker BPTH. The last closing price for Bio Path was $2.01. Over the last year, Bio Path shares have traded in a share price range of $ 2.00 to $ 44.80.

Bio Path currently has 678,795 shares outstanding. The market capitalization of Bio Path is $1.36 million. Bio Path has a price to earnings ratio (PE ratio) of -0.08.

BPTH Latest News

Bio-Path Holdings to Present Data at 2024 European Hematology Association Congress

HOUSTON, May 24, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...

Bio-Path Holdings to Present Data at American Society of Clinical Oncology (ASCO) Annual Meeting

HOUSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to...

U.S. Index Futures Flat Ahead of April CPI Data Release, Oil Prices Drop

U.S. index futures are virtually flat in pre-market trading this Wednesday, with Wall Street awaiting April’s consumer price index data. At 7:18 AM, Dow Jones futures (DOWI:DJI) were up 3...

Bio-Path Holdings Reports First Quarter 2024 Financial Results

Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today at 8:30 A.M. ET HOUSTON, May 15, 2024 (GLOBE NEWSWIRE...

Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024

HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) --  Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop...

Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasdaq: BPTH) (the “Company” or “Bio-Path”), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2-8.658008658012.312.382561452.08710513CS
4-0.53-20.07575757582.643.01992999612.61631962CS
12-3.98-65.35303776686.097.6699215378384.14517242CS
26-7.74-78.5786802039.8512.3659827833264.52421713CS
52-32.49-93.90173410434.644.82115458410.55933482CS
156-116.29-98.2179054054118.4172.398252493639.15177996CS
260-292.09-99.2828008158294.2486.8252542791.21513472CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
AKANAkanda Corporation
$ 4.07
(70.29%)
39.11M
TKLFYoshitsu Company Ltd
$ 0.3496
(53.33%)
84.5M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M
MRUSMerus NV
$ 59.92
(35.97%)
6.91M
VSTMVerastem Inc
$ 4.0901
(-66.42%)
19.68M
TOIIWOncology Institute Inc
$ 0.0443
(-55.61%)
280.55k
SNSESensei Biotherapeutics Inc
$ 0.7912
(-45.43%)
1.41M
GNLXGenelux Corporation
$ 2.61
(-43.26%)
3.32M
AUVIApplied UV Inc
$ 0.32
(-33.33%)
5.18M
LUCYInnovative Eyewear Inc
$ 0.983
(428.49%)
944.4M
GWAVGreenwave Technology Solutions Inc
$ 0.0843
(-4.85%)
428.98M
NCPLNetcapital Inc
$ 0.20
(14.42%)
191.35M
HLTHCue Health Inc
$ 0.0931
(-1.27%)
160.21M
ONMDOneMedNet Corporation
$ 2.251
(53.13%)
136.04M

BPTH Discussion

View Posts
saj saj 3 weeks ago
BPTH: Bio-Path Holdings Has Been Granted Israeli Patent Number 269608 Titled "COMPOSITIONS COMPRISING P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION FOR USE IN TREATING CANCER OR AUTOIMMUNE DISEASE"
BENZINGA 8:44 AM ET 5/3/2024
👍️0
Awl416 Awl416 1 month ago
Bio-Path Holdings, Inc. Announces $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
👍️0
Monksdream Monksdream 1 month ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc
👍️0
tw0122 tw0122 1 month ago
New hi 3.85 700k float
👍️0
Monksdream Monksdream 2 months ago
BPTH new 52 lo
👍️0
Monksdream Monksdream 2 months ago
BPTH under $5
👍️0
Awl416 Awl416 2 months ago
Volatility
👍️0
Renee Renee 3 months ago
BPTH: effective Feb. 23,2024 a one for 20 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
INV4 INV4 7 months ago
Bio-Path Holdings to Host Virtual Key Opinion Leader Event to Discuss Prexigebersen and Advances in the Treatment Landscape for Acute Myeloid Leukemia

October 24, 2023

Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced it will host a virtual key opinion leader event to highlight the prexigebersen program and discuss advances in the treatment landscape for acute myeloid leukemia (AML). The conference call will be held on Monday, October 30, 2023 at 9:00 a.m. ET.
The event will be hosted by Peter Nielsen, Chief Executive Officer of Bio-Path, and will feature presentations and discussion with:

Jorge Cortes, M.D., Director, Georgia Cancer Center, Augusta University
Maro Ohanian, D.O., Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center

To access the live conference call, please call (833) 630-1956 (domestic) or (412) 317-1837 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company’s website, www.biopathholdings.com. An archived webcast will be available on the Bio-Path website approximately two hours after the event.

About Bio-Path Holdings, Inc.
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous transfusion. Bio-Path’s lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers, and BP1001-A, a drug product modification of prexigebersen, is in a Phase 1 study for solid tumors. The Company’s second product, BP1002, which targets the Bcl-2 protein, is being evaluated for the treatment of blood cancers and solid tumors, including lymphoma and acute myeloid leukemia. In addition, an IND application is expected to be filed for BP1003, a novel liposome-incorporated STAT3 antisense oligodeoxynucleotide developed by Bio-Path as a specific inhibitor of STAT3.

For more information, please visit the Company's website at http://www.biopathholdings.com.

Contact Information:

Investors

Will O’Connor
Stern Investor Relations
212-362-1200
will@sternir.com

Doug Morris
Investor Relations
Bio-Path Holdings, Inc.
832-742-1369

https://ih.advfn.com/stock-market/NASDAQ/bio-path-BPTH/stock-news/92348612/bio-path-holdings-to-host-virtual-key-opinion-lead

$BPTH
👍️0
INV4 INV4 7 months ago
Agree! Looking good.
$BPTH
👍️0
Triple nickle Triple nickle 7 months ago
Holding up pretty nice
👍️ 1
Huti Huti 7 months ago
12? We’ll see.. maybe once they get approved!
👍️0
Zardiw Zardiw 7 months ago
$BPTH - #DDAmanda Video Analysis

#DDAmanda Halloween Special: https://DDAmanda.com/SignUpHalloween164.php



Z
👍️ 1
webprods webprods 7 months ago
$BPTH Finally I got answer where BPTH going. Here you are: Target price $12. 1,500.00% up from today. Reason: FDA approval for drug ”Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc 2. Also Oct 11. 2023 News
👍️0
Zardiw Zardiw 7 months ago
+++ #DDAmanda Chart on: $BPTH :

DDAmanda lets you find these early:



Z
👍️ 1
harry crumb harry crumb 7 months ago
Out, halted. Beware of a selloff folks
👍️0
TimeFades TimeFades 7 months ago
Boom
👍️0
dinogreeves dinogreeves 7 months ago
Good luck, I had this back in the day when it made that huge run. Been watching off and on.
👍️0
jchords jchords 7 months ago
Yea. Got in pretty low on the jump. Don’t have many shares. Thanks for the info
👍️0
dinogreeves dinogreeves 7 months ago
They are waiting on from FDA for Fast Track Designation, they applied back in August, so it takes 60 days after the request. Either there is leak somewhere out there or just hedge run. If there is news tomorrow, I expect a huge run, closed very strong after hours.
👍️0
jchords jchords 7 months ago
You know what the catalyst is?
👍️0
dinogreeves dinogreeves 7 months ago
BPTH will run big tomorrow.
👍️0
jchords jchords 7 months ago
Going crazy AH
👍️0
jchords jchords 7 months ago
Lol
👍️ 1
Awl416 Awl416 7 months ago
OCG BPTH WTO

who’s responsible?
👍️ 1
Awl416 Awl416 7 months ago
Here we go again lol
👍️ 1
Monksdream Monksdream 8 months ago
BPTH new 52 week low
👍️ 1
REAGAN REAGAN 9 months ago
I could buy controlling interest in this company for $2.4m. Fire the CEO. Phase II is years away from a successful P-3 double blind. Of which would cost $200m. What could happen here is a consortium could come in and buy up 50% of the shares then juice the pump and sell them at $3.00 a share. But yes. Looks absolutely terrible here.
👍️0
Monksdream Monksdream 9 months ago
BPTH new 52 Week low
👍️0
TimeFades TimeFades 10 months ago
Bingo
👍️0
TimeFades TimeFades 10 months ago
Don’t get shook here this thang will have it’s day soon atlesst 50% bag
👍️0
TimeFades TimeFades 10 months ago
Lol
👍️0
willlbone willlbone 10 months ago
Blood Bath Holdings.
👍️0
AJ Freely AJ Freely 10 months ago
$BPTH - 👆Up 20% Pre-Market/ Current Price $1.29
👉Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia
👍️0
cfoofme cfoofme 2 years ago
Anyway, pps has been climbing slowly & steadily the last month.
👍️0
cfoofme cfoofme 2 years ago
Anyone here still holding BPTH?
👍️0
mik1234 mik1234 3 years ago
86,231 shares traded today.
👍️0
INFINITI INFINITI 3 years ago
BPTH $$$
👍️0
mik1234 mik1234 3 years ago
BPTH
👍️0
mik1234 mik1234 3 years ago
BPTH
👍️0
Pt3 Pt3 3 years ago
kool i hope this start running fda clear
👍️0
INFINITI INFINITI 3 years ago
AH will be interesting not selling $$$$$
👍️0
INFINITI INFINITI 3 years ago
Nice
👍️0
Hercules1 Hercules1 3 years ago
Tomorrow this blows right by $9
👍️0
Pt3 Pt3 3 years ago
kool got filled 6.32 ??
👍️0
INFINITI INFINITI 3 years ago
Hasn’t been blood all day nothing but green $$$$$$
👍️0
Pt3 Pt3 3 years ago
BLOOD EVRR
👍️0
INFINITI INFINITI 3 years ago
Cmon wtf
👍️0
INFINITI INFINITI 3 years ago
Back to 52wk high let’s goooo$$$
👍️0
INFINITI INFINITI 3 years ago
Breaking out today ENJOY$$$$!
👍️0

Your Recent History

Delayed Upgrade Clock